The Dentist Entrepreneur Organization and Share Moving Media Announce Joint Venture to Publish DSO-focused Dental Trade Magazine

The Dentist Entrepreneur Organization (DEO) is committed to providing emerging dental group leaders access to the connections, education, and resources they need to grow. So, The DEO is excited to announce its joint venture with Share Moving Media to form DEO Media, LLC, publisher of Efficiency In Group Practice Magazine, a resource for dentist entrepreneurs and DSO leaders.

PORTLAND, Ore. (PRWEB) December 03, 2020

The Dentist Entrepreneur Organization (The DEO) of Portland, Oregon and Share Moving Media of Lawrenceville, Georgia announce the formation of a new entity called DEO Media, LLC, a joint venture between the two organizations to publish Efficiency in Group Practice, a bi-monthly dental trade magazine focused on DSOs (dental service organizations) and group dentistry.

“We’re extremely excited to give emerging dental group leaders even more access to the people, education, and resources they need to grow,” said Jacob Puhl, CEO of The DEO. “This partnership further enables us to continue our mission to help dentist entrepreneurs and their executives fulfill their visions. We hope to have a continued positive impact on the dental community.”

Efficiency In Group Practice provides an informational and educational link between manufacturers, distributors, service providers, and dental group practices. Each issue of Efficiency covers emerging trends in dentistry, and provides content to enable group practices to capitalize on their distinct strengths and differences to reach new heights of efficiency and become more profitable.

“This new partnership positions Efficiency in Group Practice with the leadership and direction so dearly needed for a publication to thrive in these dynamic times,” said Share Moving Media CEO John Pritchard. “Now more than ever, dental group practices need insight, understanding and community to grow their practices. We are excited to partner with Jacob Puhl and the entire DEO team to help provide just that!”

Under the partnership, The DEO and Share Moving Media will collaborate on editorial, sales, marketing and distribution of the industry-leading publication. Jacob Puhl, partner and CEO of the Dentist Entrepreneur Organization, will be Efficiency’s publisher.

The first issue from DEO Media, LLC will be the January-February 2021 edition of Efficiency In Group Practice.

About

The Dentist Entrepreneur Organization© (DEO) provides a context, a professional resource, and a peer-to-peer network within a well-managed organizational structure. For more information, visit https://deodentalgroup.com/.

Share Moving Media is a leading publishing and content company providing information, communication and educational services to providers, manufacturers and distributors involved in the business of healthcare. For more information, visit https://sharemovingmedia.com/.

For more information on Efficiency in Group Practice, visit https://www.dentalgrouppractice.com/.

For the original version on PRWeb visit: https://www.prweb.com/releases/the_dentist_entrepreneur_organization_and_share_moving_media_announce_joint_venture_to_publish_dso_focused_dental_trade_magazine/prweb17583024.htm

Source Article

Read more

Gulf Medical University College of Medicine and ScholarRx Announce Medical Education Partnership

LOUISVILLE, Ky., Dec. 2, 2020 /PRNewswire/ — Today the Gulf Medical University College of Medicine (GMU) and ScholarRx announced a collaboration to further the College’s educational mission. GMU has adopted the Rx Bricks online service from ScholarRx, a revolutionary digital learning platform that supports the curriculum and enhances pre-clinical instruction.

ScholarRx (PRNewsfoto/ScholarRx)

Prof. Hossam Hamdy, Chancellor, Gulf Medical University states, “Gulf Medical University’s partnership with ScholarRx ensures that the content of the medical curriculum is benchmarked with similar top U.S. medical colleges using the same program. The Rx Bricks of ScholarRx provide our students with up-to-date medical knowledge through educationally sound courses delivered by expert faculty. As a leading medical university in the Middle East, Gulf Medical University will contribute to the continuous development of ScholarRx by integrating its Virtual Patient Learning (VPL) technology in the Rx Bricks, conducting research, and evaluating the educational impact of ScholarRx.  I am sure our students and faculty will appreciate the value of ScholarRx.” 

GMU uses the innovative Rx Bricks digital learning platform from ScholarRx to better engage and align medical students with the curriculum. This has become especially important as more learning is taking place online. With this new set of resources, faculty teaching GMU students can:

  • Assign specific Rx Bricks through their learning management system
  • Use question banks accompanying the Rx Bricks for both formative and summative assessments, and
  • Provide foundational support to their virtual patient learning sessions.

“Collaboration with ScholarRx has enriched and added value to our existing online learning resources, as the College of Medicine has been able to seamlessly integrate the Rx Bricks in the medical curriculum. Faculty and students alike have embraced it with ease due to the user-friendly nature of the resource,” said Prof. Manda Venkatramana, Vice-Chancellor Academics and Dean, College of Medicine at Gulf Medical University.

“GMU has developed into a leading institution for medical education in the Middle East under the visionary leadership of Chancellor Hamdy and Vice-Chancellor Manda,” said Dr. Tao Le, Founder and CEO of ScholarRx. “We are pleased to support their remarkable work in digital curricular innovation.”

About Gulf Medical University College of Medicine
The vision of the university is to be a leading international academic healthcare institution through the integration of quality health professions education, research, healthcare, and social accountability for sustainable community development. The College of Medicine, in existence since 1998, has managed to not only impart quality medical education, but has also created a network of healthcare services, a conducive research milieu, and developed unique related avenues for professional development, policy, and leadership to meet the healthcare needs of the nation and the region.

About ScholarRx
ScholarRx is a mission-driven education organization currently serving over 150,000 medical students and physician learners annually.  ScholarRx has developed a revolutionary componentized, multi-competency curricular platform that empowers medical schools and their faculty to rapidly develop high-quality education experiences, even in resource-poor environments.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gulf-medical-university-college-of-medicine-and-scholarrx-announce-medical-education-partnership-301183960.html

SOURCE ScholarRx

Source Article

Read more

Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration

BETHESDA, Md. and BALTIMORE, Nov. 30, 2020 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”), today announced a research collaboration with the University of Maryland School of Medicine (UMSOM), to investigate Gain’s structurally targeted allosteric regulators (STARs) in cellular models of neuronopathic Gaucher disease (nGD) and Parkinson’s disease (PD). STARs are proprietary small molecules targeting novel allosteric binding sites on enzymes. These small molecule drug candidates are designed to cross the blood brain barrier and penetrate other hard to treat organs such as bone and cartilage, stabilize the effective enzyme to restore function and reduce toxic substrate. Research will be led by Ricardo A. Feldman, Ph.D., Associate Professor, of Microbiology and Immunology in UMSOM.

Under the terms of the collaboration, UMSOM will investigate Gain’s STAR candidates in macrophage and neuronal models of nGD and GBA-associated PD. These diseases are characterized by mutations in the GBA gene, where misfolding of the enzyme encoded by GBA (beta-glucocerebrosidase (GCase)) interferes with its normal transport to the lysosome. The research program will aim to further elucidate the mechanism of action of Gain’s STAR candidates by studying their effect on GCase, including GCase’s enzyme activity and transport to the lysosome. Additionally, other effects such as prevention of alpha-synuclein aggregation in PD dopaminergic neurons will be evaluated.

“We are exceedingly proud to be advancing our work in nGD and Parkinson’s in close collaboration with the University of Maryland School of Medicine,” said Eric Richman, Chief Executive Officer at Gain. “The expertise and experience of UMSOM and Dr. Feldman will be instrumental as we work to further validate the exciting potential of Gain’s STAR candidate for these devastating diseases. I am confident these foundational studies will bring us closer to a potential new treatment option for those with these disorders.”

Dr. Feldman added, “Our laboratory has used human induced pluripotent stem cell (iPSC) models of GD and GBA-associated PD to uncover the molecular mechanisms leading to these diseases. We have also developed very sensitive assays to evaluate the therapeutic efficacy of small molecules in reversing the phenotypic abnormalities caused by mutant GBA in the cell types affected by these diseases, including macrophages and neuronal cells. I have been impressed by Gain’s initial results evaluating the potential of STARs in correcting enzyme misfolding and restoring function, and look forward to working with Gain’s team to further advance its program to treat these diseases.”

Gain and UMSOM intend to report initial data from the collaboration in the first half of 2021.

About Gain Therapeutics, Inc.
Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for

Read more

Novant Health, UNC Health, UNC School of Medicine announce agreement to partner across North Carolina

Novant Health, UNC Health and UNC School of Medicine have reached an agreement to expand medical education, research and clinical services to Novant Health facilities and other locations across North Carolina.

This partnership will expand the recently approved relationship between these organizations in New Hanover County to include Mecklenburg, Forsyth and other counties, with an additional focus to find innovative solutions to enhance care in rural areas.

The partnership will begin with locating a UNC School of Medicine branch campus at Novant Health Presbyterian Medical Center in Charlotte and will enhance and serve as an important training site for learners. It also gives more students access to learn at the best medical school for primary care in the country, according to U.S. News & World Report, and will expand the pipeline for high-quality physicians available to serve North Carolinians. In addition, the expansion of UNC School of Medicine’s Kenan Primary Care Medical Scholars Program will train more students to work in rural and under-resourced communities with enhanced training for care in those communities across North Carolina.

Additionally, clinical trials and studies from UNC School of Medicine’s world-renowned researchers will provide new treatment options for patients in Novant Health facilities.

Collaboration on population health has the potential to make a tremendous impact on the health of North Carolina. Together, through advanced analytics and proven population health strategies, more data will allow these partners to address community health challenges, such as COVID-19, opioid addiction, social determinants of health and health equity, to name a few.

“I am pleased that Forsyth and Mecklenburg counties, and the surrounding communities, will benefit from a collaboration between Novant Health and UNC Health and School of Medicine,” said Carl S. Armato, Novant Health president and CEO. “Our organizations are culturally aligned and committed to delivering safe, high-quality and affordable care while improving health equity in the communities we serve. This alignment allows us to expand access to medical education and clinical research across the state.”

“I am excited for the opportunities ahead for Novant Health, UNC Health and UNC School of Medicine to build a healthier North Carolina and to train more physicians for North Carolina,” said Dr. Wesley Burks, CEO of UNC Health and dean of UNC School of Medicine. “Our partnership will impact health in North Carolina for decades to come.”

More details will be announced as the partnership is finalized.

Source Article

Read more

Telix Pharmaceuticals and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market

MELBOURNE, Australia and HONG KONG, Nov. 02, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into a strategic licence and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited (‘China Grand Pharma’) for Telix’s portfolio of Molecularly-Targeted Radiation (‘MTR’) products.

Telix has appointed China Grand Pharma as its exclusive partner for the Greater China market (‘Territory’)1 and grants China Grand Pharma exclusive development and commercialisation rights to Telix’s portfolio of prostate, renal and brain (glioblastoma) cancer imaging and therapeutic MTR products in the Territory.

Leveraging off China Grand Pharma’s capabilities and infrastructure in China, Telix will enter a significant oncology market, and by partnering with Telix, China Grand Pharma will build on its pipeline of innovative products for Greater China, as well as its strategy in Nuclear Medicine.

The material terms of the partnership include:

Therapeutic Products

  • US$25M (~AU$35M) up-front non-refundable prepayment to Telix, to be credited against future regulatory and commercial milestone payments.

  • Up to US$225M (~AU$315M) in regulatory and commercial milestone payments to Telix, across Telix’s existing therapeutic products portfolio.

  • Program-related investment estimated at up to US$65M (~AU$90M) for clinical costs associated with the development of the therapeutic products in the Territory, to align with Telix’s global clinical development programs.

  • Royalties on therapeutic product sales in the Territory, in addition to milestone payments.

Imaging Products

  • Exclusive commercial partnership (sales, marketing, distribution) for Telix’s core imaging product portfolio:

    • TLX250-CDx (89Zr-Girentuximab) for renal cancer, and;

    • TLX591-CDx (68Ga-PSMA), TLX599-CDx (99Tc-PSMA) for prostate cancer.

Strategic Equity Investment

Additionally, China Grand Pharma will make a simultaneous one-time strategic equity investment of US$25M (~AU$35M) in Telix. The investment is in the form of a private placement to China Grand Pharma of 20,947,181 fully paid ordinary Telix shares representing a post-issue holding by China Grand Pharma of 7.62%. Shares will be issued at a price of AU$1.69, based on the 10-day volume-weighted average price (‘VWAP’) for Telix shares up to and including 28th October 2020. Shares will be issued no later than November 06 2020, following receipt of the placement proceeds. Shares issued to China Grand Pharma are subject to a holding lock and will not be able to be traded for a period of 12 months from the date of issue. In addition, China Grand Pharma is subject to a standstill provision and is unable to trade in Telix shares for a period of 12 months.

Telix Pharmaceuticals CEO, Dr. Chris Behrenbruch stated, “Telix’s mission is to be a leading global oncology company and China is an important future market for our products. We are pleased to be working with China Grand Pharma to deliver our diagnostic imaging and therapeutic products to cancer patients in China. Considering the successful acquisition of Sirtex Medical Limited with joint venture private equity partner CDH Genetech Limited2 and subsequent approval of a New Drug Application filing for SIR-Spheres® by the National Medical Products Administration (‘NMPA’) of the

Read more

Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial

Amgen and Eisai to Participate in the Immune Modulation Domain of REMAP-COVID, an Adaptive Clinical Trial to Test Interventions for Patients Hospitalized With COVID-19

Amgen’s Apremilast and Eisai’s Eritoran to Be Evaluated Across Multiple International Trial Sites Within the REMAP Network

Global Coalition for Adaptive Research (LOS ANGELES, CA), Amgen (THOUSAND OAKS, CA), and Eisai Co., Ltd. (TOKYO, Japan “Eisai”) — The Global Coalition for Adaptive Research (GCAR) in collaboration with Amgen and Eisai Co., Ltd., today announced enrollment of the first patient in the immune modulation domain of REMAP-COVID, a sub-study of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19. Amgen’s apremilast and Eisai’s investigational eritoran are being evaluated as potential therapeutic agents.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005657/en/

REMAP-CAP was developed to test treatments for severe pneumonia both in non-pandemic and pandemic settings. In February 2020, REMAP-CAP rapidly pivoted to its pandemic mode (the REMAP-COVID sub-study), as per its original intent, to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients. This trial is a multicenter, randomized platform study, with treatments tested within groupings or “domains” based on pathway or mechanism of action.

The trial is being conducted in the multi-hospital UPMC (University of Pittsburgh Medical Center) health system along with over 20 hospitals in the United States. Additional global sites across the trial network will follow. University of Pittsburgh is serving as the U.S. Regional Coordinating Center.

“Partnering with the biopharmaceutical industry to be able to efficiently test well-understood targeted agents is critical to understanding treatment paradigms for COVID-19 patients,” says Derek Angus, MD, MPH, FRCP, U.S. Principal Investigator of REMAP and Chief Healthcare Innovation Officer, UPMC Health System. “Today’s announcement marks an important milestone in the collaboration between industry and the scientific and academic community to work collectively to evaluate potentially promising therapies to support patients hospitalized with COVID-19.”

Amgen’s apremilast is an oral drug which inhibits the activity of PDE4 (Phosphodiesterase 4), an enzyme found in inflammatory cells in the human body. By inhibiting PDE4, apremilast is thought to modulate the production of inflammatory cytokines and other mediators, which may prove helpful in inhibiting the inflammatory response associated with the signs, symptoms and pulmonary involvements observed in some COVID-19 patients. Apremilast is currently approved for use in more than 45 countries as an oral treatment for inflammatory diseases including moderate to severe plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behcet’s disease.

“Amgen believes that, based on its mechanism of action, apremilast might help prevent the respiratory distress seen in moderate to severe-stage adult COVID-19 patients,” said David M. Reese, M.D., Executive Vice President of Research and Development at Amgen. “We are proud to be joining REMAP-COVID, which is an important and innovative effort utilizing a platform approach and has the potential to rapidly identify whether apremilast

Read more

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy

Collaboration combines Solid’s differentiated microdystrophin construct and Ultragenyx’s HeLa PCL manufacturing platform for use with AAV8 and variants

Solid receives $40 million upfront via equity investment at a premium; up to $255 million in milestones plus royalty payments

Solid retains exclusive rights to all other uses of its microdystrophins, including its existing SGT-001 program

NOVATO, Calif. and CAMBRIDGE, Mass., Oct. 23, 2020 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced a strategic collaboration and license agreement to focus on the development and commercialization of new gene therapies for Duchenne. The parties will collaborate to develop products that combine Solid’s differentiated microdystrophin construct, Ultragenyx’s HeLa producer cell line (PCL) manufacturing platform, and AAV8 variants. The collaboration also brings together Solid’s expertise in muscle biology and Ultragenyx’s expertise in bringing novel therapies to patients with rare diseases.

Under the terms of the collaboration, Solid granted Ultragenyx an exclusive license for any pharmaceutical product that expresses Solid’s proprietary microdystrophin construct from AAV8 and variants thereof in clade E for use in the treatment of Duchenne and other diseases resulting from lack of functional dystrophin, including Becker muscular dystrophy. Ultragenyx has made a $40 million investment in Solid and has agreed to pay up to $255 million in cumulative milestone payments per product upon achievement of specified milestone events, and tiered royalties on worldwide net sales at low double digit to mid-teens percentages. Upon achievement of proof-of-concept, Solid has the right to opt-in to co-fund collaboration programs in return for participation in a profit share or increased royalty payments.

“We believe that Solid’s microdystrophin is best-in-class with its unique neuronal nitric oxide synthase binding domain,” said Emil D. Kakkis, MD, PhD, Chief Executive Officer and President of Ultragenyx. “By using an AAV8 variant validated in prior human and other studies combined with our scalable, efficient HeLa producer cell line platform, we believe we can leverage our mutual strengths to develop a high-quality AAV-based treatment alternative for Duchenne.”

“Ultragenyx has a demonstrated track record of success in developing and commercializing innovative therapies for rare diseases,” said Ilan Ganot, Co-Founder, President and Chief Executive Officer at Solid Biosciences. “We believe it is the partner of choice for exploring new gene therapy opportunities for patients with Duchenne.”

Solid’s proprietary microdystrophin construct has exhibited functional benefit in preclinical models. In preclinical studies, animals expressing a microdystrophin capable of restoring neuronal nitric oxide synthase (nNOS) resisted fatigue better than those expressing a microdystrophin that does not. Patients dosed with Solid’s proprietary microdystrophin construct at the 2E14 vg/kg dose in Solid’s ongoing IGNITE DMD clinical trial have also preliminarily demonstrated nNOS activity and function, further validating these preclinical results. Solid expects to dose the next patient in the IGNITE DMD clinical

Read more

ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

Partnership Accelerates Development Path for Mirvetuximab in Greater China and Expands Huadong Medicine’s Oncology Portfolio with Innovative ADC

Combines ImmunoGen’s Lead Clinical Program with Huadong’s Regional Oncology Expertise

ImmunoGen to Receive $40 Million Upfront Payment and is Eligible to Receive Up to $265 Million in Potential Development, Regulatory, and Commercial Milestone Payments

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd., today announced that the companies have entered into an exclusive collaboration to develop and commercialize mirvetuximab soravtansine in mainland China, Hong Kong, Macau, and Taiwan (Greater China). ImmunoGen will retain all rights to mirvetuximab in the rest of the world.

This collaboration provides ImmunoGen with access to the second largest pharmaceutical market in the world via Huadong Medicine’s development, regulatory, and commercial capabilities, while supporting Huadong Medicine’s growth strategy to build a deep portfolio of oncology, endocrinology, and autoimmunology candidates. Mirvetuximab adds a compelling late-stage oncology asset to Huadong Medicine’s portfolio.

“With extensive regional experience, the right development and regulatory capabilities, and access to a deep local network of hospitals and clinics across Greater China, Huadong Medicine is an ideal partner for us,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer. “This collaboration reflects mirvetuximab’s potential to deliver meaningful value to ovarian cancer patients as well as our ability to translate our work in ADCs into long-term relationships that create sustainable value for ImmunoGen and our partners. We look forward to working closely with Huadong Medicine to develop and commercialize mirvetuximab in Greater China as we advance the mirvetuximab program and prepare for the first potential commercial launch in the United States in 2022.”

“ImmunoGen is a leader in the development of ADCs for the treatment of cancer and this partnership provides us with a late-stage asset that will enable us to further expand our pipeline of innovative oncology programs,” said Liang Lu, Chairman of Huadong Medicine. “The compelling clinical data generated to date highlights mirvetuximab’s potential to be a promising therapy for an extremely difficult to treat disease and we look forward to beginning its development as we seek to meet the growing needs of ovarian cancer patients in Greater China.”

Under the terms of the agreement, ImmunoGen will receive an upfront payment of $40 million and is eligible to receive additional milestone payments of up to $265 million as certain development, regulatory, and commercial objectives are achieved. ImmunoGen is also eligible to receive low double digit to high teen royalties as a percentage of mirvetuximab commercial sales by Huadong Medicine in Greater China.

Huadong Medicine will be responsible for the development as well as potential regulatory submissions and commercialization of mirvetuximab in Greater China pursuant to input from a joint steering committee comprised of individuals from both companies. Huadong Medicine will also have the opportunity to participate in global clinical studies of mirvetuximab conducted by ImmunoGen. ImmunoGen will continue

Read more